Technical Analysis for ALZN - Alzamend Neuro, Inc.

Grade Last Price % Change Price Change
C 0.97 4.30% 0.04
ALZN closed up 4.3 percent on Monday, March 18, 2024, on 60 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bullish Engulfing Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 50 DMA Bearish 4.30%
MACD Bearish Signal Line Cross Bearish 4.30%
NR7 Range Contraction 4.30%
Narrow Range Bar Range Contraction 4.30%

   Recent Intraday Alerts

Alert Time
Rose Above 20 DMA about 12 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Rose Above Previous Day's High about 12 hours ago
Up 5% about 12 hours ago
Possible NR7 about 13 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Biology Medication Neuroscience Alzheimer's Disease Dementia Neurodegenerative Diseases Psychiatric Diagnosis Amyloidosis Neurodegeneration Preclinical Stage Biopharmaceutical Psychiatric Disorders Treatment Of Neurodegenerative Diseases Treatment Of Alzheimer's

Is ALZN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.032
52 Week Low 0.1132
Average Volume 54,392
200-Day Moving Average 0.70
50-Day Moving Average 0.94
20-Day Moving Average 0.99
10-Day Moving Average 1.08
Average True Range 0.10
RSI (14) 48.45
ADX 24.87
+DI 27.35
-DI 18.03
Chandelier Exit (Long, 3 ATRs) 1.00
Chandelier Exit (Short, 3 ATRs) 1.14
Upper Bollinger Bands 1.21
Lower Bollinger Band 0.77
Percent B (%b) 0.45
BandWidth 43.87
MACD Line 0.03
MACD Signal Line 0.04
MACD Histogram -0.0107
Fundamentals Value
Market Cap 6.42 Million
Num Shares 6.62 Million
EPS -2.28
Price-to-Earnings (P/E) Ratio -0.43
Price-to-Sales 0.00
Price-to-Book 7.23
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.11
Resistance 3 (R3) 1.11 1.06 1.08
Resistance 2 (R2) 1.06 1.03 1.06 1.07
Resistance 1 (R1) 1.02 1.01 1.04 1.02 1.07
Pivot Point 0.97 0.97 0.99 0.97 0.97
Support 1 (S1) 0.93 0.94 0.95 0.93 0.87
Support 2 (S2) 0.88 0.92 0.88 0.87
Support 3 (S3) 0.84 0.88 0.86
Support 4 (S4) 0.84